AVUS Fees and Costs — Avantis U.S. Equity ETF
Data updated: 2026-07-29
The net expense ratio is 0.15%. There are no sales loads or redemption fees. In fiscal 2024 the fund paid $37K in broker commissions, 0.0006% of average net assets, and portfolio turnover was 2%.
AVUS Fees and Expenses
Annual operating expenses and sales charges of AVUS. Prospectus, as of January 1, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.15% |
| 12b-1 fee | — |
| Other expenses | 0.00% |
| Gross expense ratio | 0.15% |
| Fee waiver | — |
| Net expense ratio | 0.15% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | No |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
AVUS Costs Over Time
On $10,000 invested in AVUS, assuming 5% a year before costs, total costs come to $96 over 5 years, cutting the return by 0.16% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.15%) | $16 | $50 | $87 |
| Trading costs (broker commissions) | $0 | $0 | $0 |
| Lost growth on money paid in costs | $0 | $2 | $9 |
| Total costs | $16 | $52 | $96 |
| Value after costs | $10,484 | $11,524 | $12,667 |
| Impact on return, per year | 0.16% | 0.16% | 0.16% |
AVUS Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending August 31, 2024.
- Explicit cost rate (commissions ÷ average net assets): 0.0006%
- Total broker commissions: $37K
- Bought from dealers (principal trades, not a cost): $2.8M
- Portfolio turnover (prospectus): 2%
- Securities on loan, average value: $9.7M
- Net income from securities lending: $150K (0.003% of average net assets)
AVUS Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Bank of America Merrill Lynch | $10K | 27.37% |
| Jefferies LLC | $10K | 25.61% |
| Sanford C. Bernstein | $9K | 24.32% |
| J.P. Morgan Securities | $5K | 14.58% |
| Citadel Securities CSHC US LLC | $2K | 4.79% |
| UBS Warburg | $1K | 2.76% |
| Goldman Sachs | $182 | 0.49% |
| Morgan Stanley | $22 | 0.06% |
| Barclays Capital | $7 | 0.02% |
| Evercore ISI Investment Group | $3 | 0.01% |
AVUS Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| Monster Beverage Corp | $1.8M | 64.11% |
| Overseas Shipholding Group A | $311K | 11.07% |
| Alpine Immune Sciences Inc | $288K | 10.23% |
| Deciphera Pharmaceuticals | $182K | 6.46% |
| Morphic Holding Inc | $181K | 6.43% |
| Rayzebio In | $33K | 1.17% |
| Thorne Healthtech Inc | $15K | 0.53% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.